{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma%2C+Skin&page=14",
    "query": {
      "condition": "Melanoma, Skin",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 2054,
    "total_pages": 206,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma%2C+Skin&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma%2C+Skin&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T05:18:22.543Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02244749",
      "title": "Role of Metabolic Enzymes in Non-Melanoma Skin Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Skin Cancer"
      ],
      "interventions": [
        {
          "name": "skin specimen",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2011-03",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2022-11-01",
      "last_synced_at": "2026-11-19T05:18:22.543Z",
      "location_count": 2,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02244749"
    },
    {
      "nct_id": "NCT01313429",
      "title": "Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcoma",
        "Melanoma",
        "Epithelial Malignancies",
        "Pleural Malignancies"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Allogenic tumor Cell Vaccine (K562)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 19,
      "start_date": "2011-03-04",
      "completion_date": "2020-02-26",
      "has_results": false,
      "last_update_posted_date": "2020-03-03",
      "last_synced_at": "2026-11-19T05:18:22.543Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01313429"
    },
    {
      "nct_id": "NCT07660666",
      "title": "Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Electronic Health Record Review",
          "type": "OTHER"
        },
        {
          "name": "Internet-Based Intervention",
          "type": "OTHER"
        },
        {
          "name": "Patient Navigation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-11-01",
      "completion_date": "2029-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-11-19T05:18:22.543Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07660666"
    },
    {
      "nct_id": "NCT03829501",
      "title": "A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of Head and Neck",
        "Non-small Cell Lung Cancer",
        "Hepatocellular Carcinoma",
        "Esophageal Cancer",
        "Gastric Cancer",
        "Melanoma",
        "Renal Cell Carcinoma",
        "Pancreatic Cancer",
        "Cervical Cancer",
        "Triple Negative Breast Cancer",
        "Advanced Cancer",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "Alomfilimab",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kymab Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 222,
      "start_date": "2019-01-28",
      "completion_date": "2024-10-03",
      "has_results": true,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-11-19T05:18:22.543Z",
      "location_count": 6,
      "location_summary": "Duarte, California • New Haven, Connecticut • Orlando, Florida + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03829501"
    },
    {
      "nct_id": "NCT04038619",
      "title": "Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colitis",
        "Diarrhea",
        "Malignant Genitourinary System Neoplasm",
        "Melanoma",
        "Lung Cancer",
        "Ovarian Cancer",
        "Uterine Cancer",
        "Breast Cancer",
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "Fecal Microbiota Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Loperamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2021-02-01",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-11-19T05:18:22.543Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04038619"
    },
    {
      "nct_id": "NCT05155254",
      "title": "IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "IO102-IO103",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IO Biotech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 407,
      "start_date": "2022-05-17",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2025-08-28",
      "last_synced_at": "2026-11-19T05:18:22.543Z",
      "location_count": 4,
      "location_summary": "Orange City, Florida • Orlando, Florida • Buffalo, New York + 1 more",
      "locations": [
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05155254"
    },
    {
      "nct_id": "NCT03132922",
      "title": "MAGE-A4ᶜ¹º³²T for Multi-Tumor",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Urinary Bladder Cancer",
        "Melanoma",
        "Head and Neck Cancer",
        "Ovarian Cancer",
        "Non-Small Cell Lung Cancer",
        "Esophageal Cancer",
        "Gastric Cancer",
        "Synovial Sarcoma",
        "Myxoid Round Cell Liposarcoma",
        "Gastroesophageal Junction"
      ],
      "interventions": [
        {
          "name": "Autologous genetically modified MAGE-A4ᶜ¹º³²T cells",
          "type": "GENETIC"
        },
        {
          "name": "Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "RADIATION"
      ],
      "sponsor": "USWM CT, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 71,
      "start_date": "2017-05-15",
      "completion_date": "2032-09",
      "has_results": true,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-11-19T05:18:22.543Z",
      "location_count": 10,
      "location_summary": "Miami, Florida • Tampa, Florida • St Louis, Missouri + 6 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03132922"
    },
    {
      "nct_id": "NCT04474301",
      "title": "Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19 Infection",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1152,
      "start_date": "2020-06-11",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-11-19T05:18:22.543Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04474301"
    },
    {
      "nct_id": "NCT03052205",
      "title": "A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Solid Tumors",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "IMO-2125",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Idera Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2017-06-09",
      "completion_date": "2019-10-04",
      "has_results": false,
      "last_update_posted_date": "2020-02-11",
      "last_synced_at": "2026-11-19T05:18:22.543Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • San Francisco, California + 5 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03052205"
    },
    {
      "nct_id": "NCT00094107",
      "title": "Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Skin Neoplasms"
      ],
      "interventions": [
        {
          "name": "Axitinib [AG-013736]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2004-12",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2012-06-26",
      "last_synced_at": "2026-11-19T05:18:22.543Z",
      "location_count": 11,
      "location_summary": "Orange, California • Miami Beach, Florida • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00094107"
    }
  ]
}